21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
23:28 , Nov 30, 2017 |  BC Extra  |  Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

In an article published in the Journal of Experimental Medicine , researchers at Beth Israel Deaconess Medical Center and colleagues showed that resolvins, a class of lipids, can suppress the pro-cancer activity of tumor debris...
19:02 , Oct 27, 2017 |  BC Week In Review  |  Financial News

ADC raises $200M private placement

On Oct. 23, antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC...
22:06 , Oct 26, 2017 |  BioCentury  |  Finance

Pays to stay private

While ADC Therapeutics S.A. has the hallmarks of a biotech ready for the public markets, the Swiss cancer company decided to stay private with its latest financing, citing the relative cost of capital. The oversubscribed...
09:25 , Oct 23, 2017 |  BC Extra  |  Financial News

ADC Therapeutics raises $200M

Antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC Therapeutics plans to...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
04:34 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Seciera: Ph III Emerald data

Top-line data from the double-blind, U.S. Phase III Emerald trial in 744 patients with dry eye disease showed that 0.09% Seciera met the primary endpoint of improving tear production as measured Schirmer’s test score from...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Financial News

ADC Therapeutics completes venture financing

ADC Therapeutics S.A. , Epilanges, Switzerland  Business: Cancer  Date completed: 2016-10-18  Type: Venture financing  Raised: $105 million  Investors: Auven Therapeutics Management; Wild Family Office; AstraZeneca plc ; and other undisclosed investors ...
07:00 , Oct 18, 2016 |  BC Extra  |  Financial News

ADC Therapeutics raises $105M

Oncology company ADC Therapeutics S.a.r.l. (Lausanne, Switzerland) raised $105 million in an oversubscribed round from existing investors Auven Therapeutics Management LLLP (St. Thomas, Virgin Islands), the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Undisclosed...